Navigation Links
Bcureful® Helps Fund Promising Tuberous Sclerosis Complex Research Project at NYU Langone Medical Center
Date:9/27/2013

New York, NY (PRWEB) September 27, 2013

Bcureful® presented a check in the amount of $15,000.00 to Dr. Orrin Devinsky, Director of the Comprehensive Epilepsy Center at NYU Langone Medical Center, for his upcoming everolimus research project. Bcureful Board members Lori Nerheim of Chicago and Laurie Marshall of New York City presented the check to Dr. Devinsky.

“Now is one of the most exciting times in TSC research,” said Dr. Devinsky. “Among all disorders, I think TSC is one in which medical research has made some of the greatest advances in the past decade. We have identified the two TSC genes, we know where they are, we know what proteins they code for... and hope for a cure for TSC is realistic.”

This study will look at the effects of the everolimus chemotherapy drug and its impact on the brain before TSC patients undergo brain surgery. Approval by the FDA in August 2012 was based on a greater than 50% reduction in tumor volume in trial patients. The goal of this study is to understand the effects of the drug on the basic problem in TSC which is the “brakes” are removed on a critical pathway that regulates cell growth. Understanding how everolimus “puts the brakes back” on this pathway can help us to improve existing therapies, identify new targets, and hopefully understand how this drug can help control seizures.

Julie Scroggins, Founder and Chair of Bcureful, shared, “Bcureful’s mission is to accelerate research towards a cure for TSC and we are proud to make this award to NYU Langone Medical Center for this very promising study.”

The research project is ready to begin and awaiting final Investigational New Drug (IND) approvals, but had a gap in funding of $100,000.00 prior to this donation. Dr. Devinsky explained, “We need additional funding. We need it for targeted, focused, translational projects that could really make a difference for people... and there is a gap in the funding right now. There is only so much funding available for groups like ours and many others that want to do so much more to help individuals and families with TSC, but we are limited in the amount of research that we can do. Bcureful has the opportunity to fill that gap.”

“We are committed to raising the additional $85,000.00 needed to fully fund this research project and improve the future for so many affected by TSC and related conditions,” added Scroggins.

Bcureful is a 501(c)(3) non-profit organization founded to focus resources on Tuberous Sclerosis Complex, or TSC. TSC is a genetic disorder that affects 1 in 6,000 newborns causing non- malignant tumors to develop in the brain and other vital organs. Although the growths are almost always benign, they can cause devastating effects on multiple aspects of development. It is estimated that 1 to 2 million people worldwide have TSC. Research for TSC has led to breakthroughs in autism, epilepsy and cancer.

To learn more about Bcureful and make a donation, visit: http://www.Bcureful.org.

Facebook: http://www.facebook.com/Bcureful

Bcureful® Board members Lori Nerheim of Chicago and Laurie Marshall of New York City present Bcureful’s award to Dr. Orrin Devinsky, Director of the Comprehensive Epilepsy Center at NYU Langone Medical Center, to help fund his everolimus research project for Tuberous Sclerosis Complex patients.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11158886.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Positive stress helps protect eye from glaucoma
2. Exercise helps smokers to quit smoking, to remain smoke-free and to reduce the risk of death
3. Unusual protein helps regulate key cell communication pathway
4. Equal access to care helps close survival gap for young African-American cancer patients
5. First-of-its-kind Menopause Map helps women navigate treatment
6. Palliative care resource helps ease changes
7. Fertilizing bone marrow helps answer why some cancers spread to bones
8. Two-Drug Combo Helps Teens With Migraines
9. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
10. Breast MRI helps predict chemotherapys effectiveness
11. Cooling Helps Oxygen-Deprived Newborns: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... 2017 , ... Sterling Global Products is pleased to welcome ... hanging flushable wipes dispensers and/or 42 count refill packs manufactured by this Slidell, ... operates more than 350 stores throughout Texas and expanding into northern Mexico as ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... ... ... affects much more than energy – it also has mental and physical benefits. According to ... time, which can increase the risk of having a car accident. , This week ... to help you sleep better and feel better:, , Turn off ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery ... the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, ... patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional ...
(Date:4/28/2017)... ... 2017 , ... People are starting to accept that hearing aids can be ... the stigma it had when great-grandpa wore his hearing aids years ago,” said Dr. ... North American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology: